Consulting                  Chemistry Services          Contact Us                   Team                  Home                                                                                                       
                                                  Novel Hit Compounds / IP Expansion

 

 

A key element of DDM is the ability to utilize ChemoInformatics to generate novel chemical entities that are biostructural equivalents.  This allows for the generation of novel compounds that have significant affinity for a given biological target.  This technique is extremely valuable tool for:

 

  • Chemical lead development when limited biological structural information is available.

  • Rescuing projects in which the current lead series has fatal physical or physiochemical properties, particularly when combined with our DDM ADMET filters.

  • Expansion of intellectual property coverage.

 

Shown below are some examples of the application of DDM to novel hit compound generation. In each case a new novel ligand for the given biological target was identified and verified within weeks of inception of the project.

 

 

Target

Hit Details

Notes

ERK Kinase

KIN 2118, IC50 = 1.2 uM

New Novel Compound Series

Mu Opioid Receptor

KIN 2160, Ki = 0.03 uM

Improved PK Profile Verses Lead

FLT-3 Kinase

KIN 4104, IC50 = 0.14 uM

New Novel Compound Series

Aurora B Kinase

KIN 4064, IC50 = 0.39 uM

New Novel Compound Series

 

 

 


             If you have a project that could benefit from Kinentia's DDM technologies
contact us today


 

 

 

 


©2014 Kinentia Biosciences